Shionogi
SGIOYDrugs in Pipeline
38
Phase 3 Programs
18
Upcoming Catalysts
5
Next Catalyst
This month
Market Overview
Stock performance and key metrics
5 upcoming, 0 past
Naldemedine Phase 2 Est. Readout
Primary completion for Naldemedine trial (NCT05588323) in Opioid-Induced Constipation (OIC)
Source4 more catalysts beyond 14 days
Start a 7-day free trial to see all upcoming catalysts
Duloxetine Hydrochloride
Depressive Disorder
Ospemifene 60Mg Oral Tablet
Atrophy
Ospemifene (Dose 1)
Atrophy
Ospemifene 30 mg
Atrophy
Oral Glycopyrrolate Liquid
Cerebral Palsy
Meropenem
Healthcare-associated Pneumonia (HCAP)
Ospemifene 60 mg
Atrophy
Cefiderocol
Urinary Tract Infections
Ospemifene
Vaginal Dryness
Lusutrombopag
Chronic Liver Disease
S-217622
SARS-CoV-2 Infection
Baloxavir Marboxil
Influenza
CLONICEL (Clonidine HCl sustained release)
Attention Deficit Hyperactivity Disorder
S-268019-b
SARS-CoV-2
Pravafen
Combined Hyperlipidemia
Best Available Therapy
Healthcare-associated Pneumonia (HCAP)
Naldemedine
Opioid-induced Constipation
Oseltamivir
Influenza
Velneperit 400 mg
Obesity
S-2367 800 mg
Obesity
S-2367 1600 mg q.d. 54 Weeks
Obesity
Redasemtide
Acute Ischemic Stroke
S-606001
Pompe Disease
S-555739 Dose 1
Seasonal Allergic Rhinitis
BPN14770
Jordan's Syndrome
S-707106 Dose A
Type 2 Diabetes Mellitus
Sivopixant
Sleep Apnea
S-600918
Chronic Cough
S-309309
Obesity
50 mg S-777469
Atopic Dermatitis
S-892216
COVID-19
S-777469 400 mg
Atopic Dermatitis
S-2367 (velneperit)
Obesity
Ospemifene 5 mg
Atrophy
S-337395
Respiratory Syncytial Virus Infections
S-531011
Solid Tumors
S-3304
Non Small Cell Lung Cancer
Standard of Care
Gram-negative Bacterial Infections
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Duloxetine Hydrochloride | Phase 3 | Depressive Disorder | - | - |
Ospemifene 60Mg Oral Tablet | Phase 3 | Atrophy | - | - |
Ospemifene (Dose 1) | Phase 3 | Atrophy | - | - |
Ospemifene 30 mg | Phase 3 | Atrophy | - | - |
Oral Glycopyrrolate Liquid | Phase 3 | Cerebral Palsy | - | - |
Meropenem | Phase 3 | Healthcare-associated Pneumonia (HCAP) | - | - |
Ospemifene 60 mg | Phase 3 | Atrophy | - | - |
Cefiderocol | Phase 3 | Urinary Tract Infections | - | - |
Ospemifene | Phase 3 | Vaginal Dryness | - | - |
Lusutrombopag | Phase 3 | Chronic Liver Disease | - | - |
S-217622 | Phase 3 | SARS-CoV-2 Infection | - | - |
Baloxavir Marboxil | Phase 3 | Influenza | - | - |
CLONICEL (Clonidine HCl sustained release) | Phase 3 | Attention Deficit Hyperactivity Disorder | - | - |
S-268019-b | Phase 3 | SARS-CoV-2 | - | - |
Pravafen | Phase 3 | Combined Hyperlipidemia | - | - |
Best Available Therapy | Phase 3 | Healthcare-associated Pneumonia (HCAP) | - | - |
Naldemedine | Phase 3 | Opioid-induced Constipation | - | - |
Oseltamivir | Phase 3 | Influenza | - | - |
Velneperit 400 mg | Phase 2 | Obesity | - | - |
S-2367 800 mg | Phase 2 | Obesity | - | - |
S-2367 1600 mg q.d. 54 Weeks | Phase 2 | Obesity | - | - |
Redasemtide | Phase 2 | Acute Ischemic Stroke | - | - |
S-606001 | Phase 2 | Pompe Disease | - | - |
S-555739 Dose 1 | Phase 2 | Seasonal Allergic Rhinitis | - | - |
BPN14770 | Phase 2 | Jordan's Syndrome | - | - |
S-707106 Dose A | Phase 2 | Type 2 Diabetes Mellitus | - | - |
Sivopixant | Phase 2 | Sleep Apnea | - | - |
S-600918 | Phase 2 | Chronic Cough | - | - |
S-309309 | Phase 2 | Obesity | - | - |
50 mg S-777469 | Phase 2 | Atopic Dermatitis | - | - |
S-892216 | Phase 2 | COVID-19 | - | - |
S-777469 400 mg | Phase 2 | Atopic Dermatitis | - | - |
S-2367 (velneperit) | Phase 2 | Obesity | - | - |
Ospemifene 5 mg | Phase 2 | Atrophy | - | - |
S-337395 | Phase 2 | Respiratory Syncytial Virus Infections | - | - |
S-531011 | Phase 2 | Solid Tumors | - | - |
S-3304 | Phase 2 | Non Small Cell Lung Cancer | - | - |
Standard of Care | Phase 2 | Gram-negative Bacterial Infections | - | - |